Cargando…
Decreased tyrosine phosphorylation in tumour cells resistant to FCE 24517 (tallimustine).
Resistance to FCE 24517 is not related to the emergence of any of the most frequently observed phenotypes. We have found that two resistant cell lines (L1210/24517 murine leukaemia and LoVo/24517 human colon adenocarcinoma) present congenital modifications in tyrosyl phosphatase and kinase activitie...
Autores principales: | Ciomei, M., Pastori, W., Capolongo, L., Geroni, C., Melegaro, G., Pennella, G., Grandi, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1995
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034097/ https://www.ncbi.nlm.nih.gov/pubmed/8519667 |
Ejemplares similares
-
Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517).
por: Capolongo, L., et al.
Publicado: (1993) -
Biological profile of FCE 24517, a novel benzoyl mustard analogue of distamycin A.
por: Pezzoni, G., et al.
Publicado: (1991) -
In vivo anti-tumour activity of FCE 23762, a methoxymorpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.
por: Ripamonti, M., et al.
Publicado: (1992) -
Tallimustine in advanced previously untreated colorectal cancer, a phase II study.
por: Punt, C. J., et al.
Publicado: (1996) -
L1210 cells selected for resistance to methoxymorpholinyl doxorubicin appear specifically resistant to this class of morpholinyl derivatives.
por: Geroni, C., et al.
Publicado: (1994)